Friday, 16 October 2026European Markets

DOF Stock Falls By 31% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of DOF (Oslo Børs All-share Index_GI: DOF.OL) dropped by a staggering 31.17% in 21 sessions from 0.99 kr to 0.68 kr at 01:38 EST on Monday, after five successive sessions in a row of losses. Oslo Børs All-share Index_GI is rising 0.37% to 1,418.24 kr, after three sequential sessions in a row of losses.

About DOF

DOF ASA, together with its subsidiaries, owns and operates a fleet of offshore/subsea vessels. It operates a fleet of platform supply vessels (PSVs) that are used to transport oilfield products and supplies to offshore drilling and production facilities; anchor handling tug supply (AHTS) vessels used to set anchors for drilling rigs, and tow mobile drilling rigs and equipment from one location to another; and subsea vessels used for a range of subsea services. The company also provides subsea services, including project management, engineering, construction and installation, life-of-field, decommissioning/field abandonment, and survey and positioning, as well as inspection, repair, and maintenance services. In addition, it offers marine management services, such as crewing, chartering, mobilization, maintenance, refurbishment, project and new building, and compliance services. The company operates a fleet of 14 PSVs, 15 AHTSs, and 30 subsea vessels, as well as 73 remotely operated vehicles and 2 autonomous underwater vehicles. It operates in Brazil, the United Kingdom, Norway, Australia, Canada, Singapore, the United States, Argentina, Angola, and internationally. The company was founded in 1981 and is headquartered in Storebø, Norway.

Earnings Per Share

As for profitability, DOF has a trailing twelve months EPS of -15.512 kr.

Volume

Today's last reported volume for DOF is 14371187 which is 182.19% above its average volume of 5088980.

More news about DOF (DOF.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com